Phosphorylation of FAK at Tyr576 represents a critical step in the activation mechanism of this non-receptor protein tyrosine kinase. While Tyr397 serves as the primary autophosphorylation site, phosphorylation at Tyr576/577 within the activation loop is required for full catalytic activity of FAK. This phosphorylation occurs following FAK activation through integrin signaling in adherent cells .
The phosphorylation process follows a specific sequence: initial autophosphorylation at Tyr397 creates a binding site for SRC and SRC family members, which subsequently leads to phosphorylation at Tyr576/577 and additional tyrosine residues . Notably, certain kinases demonstrate site-specific phosphorylation patterns - for example, FGR specifically promotes phosphorylation at both Tyr397 and Tyr576, while FER targets Tyr577, Tyr861, and Tyr925 .
Tyrosine 576 phosphorylation status serves as a reliable biomarker for active FAK-mediated signaling and is particularly important in contexts like cell migration, adhesion, and cancer metastasis .
Phospho-PTK2 (Tyr576) antibodies demonstrate effectiveness across several key experimental applications:
Sample preparation: Include phosphatase inhibitors in lysis buffers
Controls: Include non-phosphorylated controls or blocking peptide samples
Fixation method: Compatible with formalin-fixed, paraffin-embedded tissues
Detection system: Use high-sensitivity detection systems for optimal results
Cell preparation: Methanol fixation has shown good results with HeLa cells
Counterstaining: DAPI for nuclear visualization is recommended
Provides qualitative determination of FAK (phospho Tyr576) expression
Multiple normalization methods available: anti-GAPDH antibody control, Crystal Violet whole-cell staining, and total FAK normalization
Validating antibody specificity is crucial for obtaining reliable research results. Several approaches are recommended:
Blocking peptide competition assays: Pre-incubate the antibody with the phosphorylated peptide immunogen. This should abolish specific binding in Western blots or other applications, as demonstrated in validation studies .
Phosphatase treatment: Compare samples treated with and without lambda phosphatase. Specific phospho-antibody reactivity should be eliminated after phosphatase treatment.
Stimulation experiments: Use known activators of FAK phosphorylation (e.g., PMA treatment in HT29 cells) to demonstrate increased antibody reactivity .
Cross-reactivity assessment: Confirm the antibody detects endogenous levels of FAK protein only when phosphorylated at Y576, with no cross-reactivity with other proteins or non-phosphorylated forms .
Knockout/knockdown verification: Compare signals between wild-type cells and those where FAK has been depleted to confirm signal specificity.
Commercial antibodies targeting Phospho-PTK2 (Tyr576) vary in several important aspects:
Most commonly rabbit-derived (polyclonal or monoclonal) , with recombinant monoclonal options now available for enhanced reproducibility .
Typically produced against synthesized peptides derived from human FAK surrounding the Tyr576 phosphorylation site, often covering amino acids 542-591 .
While most antibodies are validated for Western blotting, application breadth varies considerably between products, with some validated for multiple techniques including IF, IHC, IP, and ELISA .
Most commonly provided in liquid form in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide .
Most antibodies react with human, mouse, and rat samples due to high sequence conservation around the Tyr576 site .
Issue: Non-specific bands or smearing
Solutions: Increase blocking time and concentration; use alternative blocking agents (milk vs. BSA); optimize antibody dilution; increase washing duration and frequency; add low concentrations of detergent to wash buffers .
Issue: No detection of phosphorylated protein
Solutions: Verify phosphorylation status through positive controls; confirm adequate sample preparation with phosphatase inhibitors; use enhanced chemiluminescence detection; ensure appropriate transfer conditions for high molecular weight FAK (125 kDa) .
Issue: Variable detection across experiments
Solutions: Standardize cell culture conditions known to affect FAK phosphorylation; maintain consistent lysis protocols; avoid freeze-thaw cycles of both samples and antibody; use freshly prepared samples when possible .
Issue: Diffuse staining or unexpected localization
Solutions: Optimize fixation methodology; perform antigen retrieval; include appropriate blocking steps; validate with phosphopeptide competition .
FAK contains multiple phosphorylation sites that function in a coordinated manner:
Tyr397 serves as the primary autophosphorylation site, creating a binding site for SRC family kinases, which subsequently phosphorylate Tyr576/577 . This sequential activation is critical for full FAK activity.
Tyr397: Initial autophosphorylation; binding site for SH2 domain-containing proteins including SRC, PIK3R1, and SHC1
Tyr576/577: Located in the activation loop; required for maximum kinase activity
Tyr861: Associated with SRC-mediated phosphorylation and FAK conformational changes
Tyr925: Creates binding site for Grb2; implicated in the MAPK pathway
While Tyr397 phosphorylation can occur rapidly upon integrin engagement, Tyr576 phosphorylation follows as a secondary event dependent on SRC recruitment. Both Tyr397 and Tyr576 phosphorylation are primarily observed in adherent cells, alongside Ser722 phosphorylation .
Different kinases show preferences for specific FAK phosphorylation sites. For example, FER can phosphorylate Tyr577, Tyr861, and Tyr925 even in non-adherent cells, while RET directly phosphorylates FAK at Tyr576/577 but not Tyr925 .
Researchers are utilizing antibody duos (e.g., pY576/577 paired with pY925) to simultaneously track multiple FAK phosphorylation events, providing insight into activation mechanisms and signaling dynamics .
Combining immunoprecipitation using Phospho-PTK2 (Tyr576) antibodies with mass spectrometry to identify phosphorylation-dependent protein interactions and quantify phosphorylation stoichiometry .
Specialized ELISA kits allow for the detection of FAK (phospho Tyr576) in intact cells, enabling studies of how different stimulation conditions affect FAK phosphorylation across various cell lines .
Increased levels of phosphorylated FAK at Tyr576 are being investigated as potential biomarkers in various cancers, with researchers exploring correlations with tumor progression, metastasis, and therapeutic response .
This advanced technique allows visualization of protein-protein interactions involving phosphorylated FAK, providing spatial information about where activated FAK functions within cells .
Accurate quantification of phosphorylation status requires normalization to total protein levels:
Run duplicate samples on parallel gels or strip and reprobe membranes
Probe one with phospho-specific antibody and the other with total FAK antibody
Calculate the ratio of phospho-FAK to total FAK using densitometry
Include loading controls (e.g., GAPDH, β-actin) for additional normalization
Multiple normalization methods are available for cell-based ELISA systems:
Anti-GAPDH antibody serves as an internal positive control
Crystal Violet whole-cell staining determines cell density to adjust for plating differences
Anti-FAK antibody provides normalization by comparing absorbance values for phosphorylated vs. non-phosphorylated target
Present data as fold change in phosphorylation rather than absolute values to account for experimental variation. Include statistics from multiple independent experiments to establish significance of observed changes.
FAK Tyr576 phosphorylation status has significant implications in disease contexts:
Increased levels of FAK and Src proteins are found in tumors, with the FAK-Src signaling complex playing a crucial role in tumor cell behavior. Phosphorylation of FAK at Tyr576/577 is essential for this activity and may serve as a biomarker for cancer progression .
As a key regulator of cell migration, adhesion, and invasion, phosphorylated FAK at Tyr576 is implicated in the metastatic cascade. FAK activation promotes focal adhesion turnover and cytoskeletal reorganization necessary for cell movement .
FAK inhibitors are being developed as potential cancer therapeutics, with Tyr576 phosphorylation serving as a pharmacodynamic marker of drug efficacy. Monitoring this phosphorylation site helps researchers evaluate the impact of FAK-targeting compounds .
Phospho-specific antibodies against FAK Tyr576 are being used to investigate FAK activation in various experimental models including 2D and 3D cell cultures, xenografts, and tissue microarrays, providing insights into the spatial and temporal dynamics of FAK activation in different microenvironments .